System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

François Chasset is an expert in Dermatology at Tenon Hospital (France). As of October 2026, ScienceLeadR ranks François Chasset in the top 1% of experts worldwide for Autoimmune Diseases, Lupus Erythematosus, Cutaneous and Epidemiologic Studies. François Chasset has authored 339 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 3 of them ongoing. SLR score: 1,215 (community average: 125). How the SLR is computed.

LeadR Profile

François Chasset Tenon Hospital France
1 215 ScienceLeadR Reputation 1215

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Rheumatology - Immunology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2014 - 2026
Source: PubMed

Tenon Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 339

Citations

Citations: 3 964 1st author: 40 Last author: 67 Unique author: 3

Main journals

Ann Dermatol Venereol 43
J Am Acad Dermatol 37
Rev Med Interne 30
Annales de Dermatologie et de Vénéréologie - FMC 25
Annales de dermatologie et de vénéréologie, FMC 19

Best Journals

N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.
PMID 42892381 — skin, lupus erythematosus, cutaneous, safety, therapeutics, dermatology, erythema		J Am Acad Dermatol20260
ERN ReCONNET-SLICC-SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2).
PMID 42648304 — lupus erythematosus, systemic, therapeutics, erythema		Lancet Rheumatol20260
CBL Variants in Suspected Histiocytic Neoplasms: A Retrospective Study of 11 Cases.
PMID 42758873 — hematology, retrospective studies, neoplasms		Hematol Oncol20260
Diagnosis delay and burden in cutaneous lupus erythematosus burden: Analysis of two European studies.
PMID 42723510 — sexually transmitted diseases, lupus erythematosus, cutaneous, skin diseases, fatigue, diagnosis, cost of illness		J Eur Acad Dermatol Venereol20260
The spectrum of eosinophilic cellulitis (Wells' syndrome): new insights based on 114 cases.
PMID 42551694 — hypersensitivity, adrenal cortex hormones, cellulitis, eosinophils, therapeutics		J Allergy Clin Immunol Pract20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 6
Phase 3 3
Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 6
Active not recruiting 2
Unknown 2
Recruiting 1

By type:

Observational 6
Interventional 5

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 3
multicentric5to9 1
multicentricup10 4

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Long Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (CLE) (AMETHYST LTE)
2023-504863-17-00 — injections, lupus erythematosus, cutaneous, safety, signs and symptoms, therapeutics, antimalarials		Phase 3Recruiting2024
A Phase 2 Clinical Study to Assess the Safety and Efficacy of Deucravacitinib in Participants with Active DLE and or SCLE
2023-504161-22-00 — lupus erythematosus, cutaneous, safety		Phase 2Active not recruiting2021
A 2 Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565 — injections, skin, lupus erythematosus, discoid, lupus erythematosus, cutaneous, safety, pharmaceutical preparations, skin diseases, lupus erythematosus, systemic, signs and symptoms, therapeutics, antimalarials		Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS